Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.
Kopycinski J, Cheeseman H, Ashraf A, Gill D, Hayes P, Hannaman D, Gilmour J, Cox JH, Vasan S. Kopycinski J, et al. Among authors: cheeseman h. Clin Vaccine Immunol. 2012 Sep;19(9):1557-9. doi: 10.1128/CVI.00327-12. Epub 2012 Jul 25. Clin Vaccine Immunol. 2012. PMID: 22837097 Free PMC article. Clinical Trial.
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.
Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes P. Spentzou A, et al. Among authors: cheeseman h. J Infect Dis. 2010 Mar;201(5):720-9. doi: 10.1086/650492. J Infect Dis. 2010. PMID: 20132004
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD. Vasan S, et al. Among authors: cheeseman h. PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16. PLoS One. 2011. PMID: 21603651 Free PMC article. Clinical Trial.
Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials.
Kaltsidis H, Cheeseman H, Kopycinski J, Ashraf A, Cox MC, Clark L, Anjarwalla I, Dally L, Bergin P, Spentzou A, Higgs C, Gotch F, Gazzard B, Gomez R, Hayes P, Kelleher P, Gill DK, Gilmour J. Kaltsidis H, et al. Among authors: cheeseman h. J Immunol Methods. 2011 Jul 29;370(1-2):43-54. doi: 10.1016/j.jim.2011.05.007. Epub 2011 Jun 12. J Immunol Methods. 2011. PMID: 21669205 Clinical Trial.
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL. Keefer MC, et al. Among authors: cheeseman h. PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22870265 Free PMC article. Clinical Trial.
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D, Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M, Gazzard B, Fast PE, Cox JH, Laufer D. Hayes P, et al. Among authors: cheeseman h. Clin Vaccine Immunol. 2013 Mar;20(3):397-408. doi: 10.1128/CVI.00637-12. Epub 2013 Jan 23. Clin Vaccine Immunol. 2013. PMID: 23345581 Free PMC article. Clinical Trial.
Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Kopycinski J, Hayes P, Ashraf A, Cheeseman H, Lala F, Czyzewska-Khan J, Spentzou A, Gill DK, Keefer MC, Excler JL, Fast P, Cox J, Gilmour J. Kopycinski J, et al. Among authors: cheeseman h. PLoS One. 2014 Mar 7;9(3):e90378. doi: 10.1371/journal.pone.0090378. eCollection 2014. PLoS One. 2014. PMID: 24609066 Free PMC article. Clinical Trial.
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ. Cheeseman HM, et al. Hum Gene Ther. 2018 Sep;29(9):1011-1028. doi: 10.1089/hum.2018.075. Hum Gene Ther. 2018. PMID: 30027768 Free PMC article. Clinical Trial.
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Abraham S, Juel HB, Bang P, Cheeseman HM, Dohn RB, Cole T, Kristiansen MP, Korsholm KS, Lewis D, Olsen AW, McFarlane LR, Day S, Knudsen S, Moen K, Ruhwald M, Kromann I, Andersen P, Shattock RJ, Follmann F. Abraham S, et al. Lancet Infect Dis. 2019 Oct;19(10):1091-1100. doi: 10.1016/S1473-3099(19)30279-8. Epub 2019 Aug 12. Lancet Infect Dis. 2019. PMID: 31416692 Clinical Trial.
61 results